Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Epidemic Keratoconjunctivitis (EKC)

Inclusion Criteria: The patients have to meet all of the following criteria to be eligible to enter the study: * Willing and able to provide informed consent. * Men or women aged 18 years or above with onset of adenoviral EKC symptoms in at least one eye, as clinically diagnosed and with symptoms appearing within less 7 days at the time of giving informed consent. * Using adequate contraceptive measures Exclusion Criteria: * Known or suspected allergy to any ingredient of the IMP or placebo. * Symptoms correlating with EKC since more than 7 days. * Diagnosis of other significant disease(s) than EKC in the eye. * Diagnosis of bacterial or fungal ocular infections. * Use of antibiotics or corticosteroids by any route (except intravitreal corticosteroids) within 14 days prior to inclusion. Ocular antibiotics may, however, be used until 2 hours prior to first dose of IMP, but are thereafter prohibited during the study. * Use of immunosuppressive medications (including intravitreal corticosteroids) within 6 months prior to inclusion. * Use of antiviral medications within 7 days prior to inclusion. * Usage of any medication or herbal medicinal product with documented adverse reactions affecting the eyes. * Usage of any medication or herbal medicinal product for ocular administration at inclusion. * Female patients: currently pregnant or breast-feeding or intending to become pregnant during the study period. * Known or suspected drug abuse. * Usage of contact lenses during the study. * Participation in any other interventional clinical study within 30 days prior to inclusion